Wall Street brokerages forecast that Merck & Co., Inc. (NYSE:MRK) will report $1.42 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Merck & Co., Inc.’s earnings, with the highest EPS estimate coming in at $1.51 and the lowest estimate coming in at $1.33. Merck & Co., Inc. posted earnings per share of $1.51 in the same quarter last year, which would suggest a negative year-over-year growth rate of 6%. The firm is expected to issue its next earnings report on Tuesday, November 3rd.
On average, analysts expect that Merck & Co., Inc. will report full-year earnings of $5.70 per share for the current year, with EPS estimates ranging from $5.63 to $5.74. For the next financial year, analysts forecast that the firm will post earnings of $5.93 per share, with EPS estimates ranging from $4.88 to $6.53. Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Merck & Co., Inc..
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Friday, July 31st. The company reported $1.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.23. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The company had revenue of $10.87 billion during the quarter, compared to analyst estimates of $10.52 billion. During the same quarter in the previous year, the business earned $1.30 EPS. The firm’s revenue was down 7.6% on a year-over-year basis.
Several equities analysts have recently issued reports on MRK shares. SVB Leerink boosted their price target on shares of Merck & Co., Inc. from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Royal Bank of Canada reissued a “hold” rating on shares of Merck & Co., Inc. in a report on Tuesday, August 4th. Mizuho reaffirmed a “buy” rating and issued a $100.00 target price on shares of Merck & Co., Inc. in a research note on Friday, July 31st. ValuEngine raised shares of Merck & Co., Inc. from a “sell” rating to a “hold” rating in a research note on Thursday. Finally, Morgan Stanley reaffirmed a “buy” rating and issued a $89.00 target price on shares of Merck & Co., Inc. in a research note on Tuesday, June 23rd. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $94.54.
Shares of MRK stock traded down $0.25 on Friday, hitting $85.24. The stock had a trading volume of 8,923,680 shares, compared to its average volume of 7,422,512. Merck & Co., Inc. has a twelve month low of $65.25 and a twelve month high of $92.64. The firm has a market cap of $215.59 billion, a P/E ratio of 20.79, a PEG ratio of 2.22 and a beta of 0.45. The company has a current ratio of 1.32, a quick ratio of 1.05 and a debt-to-equity ratio of 0.94. The company has a fifty day moving average price of $82.09 and a two-hundred day moving average price of $79.32.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.61 per share. The ex-dividend date is Monday, September 14th. This represents a $2.44 annualized dividend and a yield of 2.86%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 47.01%.
In other news, EVP Frank Clyburn sold 18,876 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $81.55, for a total value of $1,539,337.80. Following the sale, the executive vice president now directly owns 99,639 shares of the company’s stock, valued at approximately $8,125,560.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Julie L. Gerberding sold 36,285 shares of the company’s stock in a transaction dated Friday, July 17th. The shares were sold at an average price of $80.00, for a total transaction of $2,902,800.00. Following the completion of the sale, the executive vice president now directly owns 62,862 shares in the company, valued at $5,028,960. The disclosure for this sale can be found here. Insiders have sold a total of 65,541 shares of company stock worth $5,303,782 over the last three months. Insiders own 0.28% of the company’s stock.
Hedge funds have recently modified their holdings of the company. CBIZ Investment Advisory Services LLC boosted its position in shares of Merck & Co., Inc. by 180.7% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the company’s stock worth $32,000 after acquiring an additional 271 shares in the last quarter. Toth Financial Advisory Corp acquired a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $32,000. Lion Street Advisors LLC acquired a new stake in shares of Merck & Co., Inc. during the 1st quarter worth approximately $35,000. Lake Point Wealth Management lifted its stake in Merck & Co., Inc. by 159.0% in the 1st quarter. Lake Point Wealth Management now owns 518 shares of the company’s stock valued at $40,000 after purchasing an additional 318 shares during the last quarter. Finally, Estate Counselors LLC bought a new position in Merck & Co., Inc. in the 2nd quarter valued at approximately $45,000. 73.18% of the stock is currently owned by institutional investors.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
See Also: How Do I Invest in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.